BACKGROUND: Sézary syndrome is a rare and very aggressive leukemic variant of cutaneous T-cell lymphoma characterized by extensive skin involvement and a malignant circulating CD4(+) T-cell clone which homes to the skin, over-expresses CD60, and lacks CD7, CD26 and CD49d. So far prognostic markers in this disease are limited to treatment with systemic steroids, age, serum lactate dehydrogenase, and a white blood cell count of 20×10(9)/L or higher: no other biological marker with prognostic value, especially related to malignant cells, has been described. DESIGN AND METHODS: We used flow activated cell sorting analysis to compare the distribution of the T-cell receptor-Vβ repertoire and several surface molecules (CD7, CD26, CD49d and CD60) within the circulating CD4(+) T-cell population in 62 patients with Sézary syndrome, 180 with mycosis fungoides, 6 with B-cell lymphomas, and 19 with chronic eczema. We calculated the 5-year overall survival of patients with Sézary syndrome after first hospital admission using Kaplan-Meier product-limit estimates and hazard ratios from the Cox proportional hazards model. RESULTS: We found that both higher number of CD60(+) and lower number of CD49d(+) cells within circulating CD4(+) T cells at disease presentation were significantly associated with a lower probability of survival. An exceedingly high risk of death was observed for patients with a combination of a high proportion of CD4(+)CD60(+) cells (≥ 0.5×10(9)/L) and low proportion of CD4(+)CD49d(+) cells (<0.5×10(9)/L) (hazard ratio = 12.303, 95% confidence interval 1.5-95.9; P<0.02). In addition, a skewed usage of T-cell receptor-Vβ subfamilies was observed in the circulating T-cell clone for 61.9% of all patients with Sézary syndrome, T-cell receptor-Vβ 2 and 5.1 subfamilies being the most frequently represented (42.8%), followed by T-cell receptor-Vβ 12 and 13.1. CONCLUSIONS: In this study we showed that up-regulation of CD60 and down-regulation of CD49d on circulating CD4(+) T cells are two useful markers for predicting a very poor outcome in patients with Sézary syndrome.
BACKGROUND: Sézary syndrome is a rare and very aggressive leukemic variant of cutaneous T-cell lymphoma characterized by extensive skin involvement and a malignant circulating CD4(+) T-cell clone which homes to the skin, over-expresses CD60, and lacks CD7, CD26 and CD49d. So far prognostic markers in this disease are limited to treatment with systemic steroids, age, serum lactate dehydrogenase, and a white blood cell count of 20×10(9)/L or higher: no other biological marker with prognostic value, especially related to malignant cells, has been described. DESIGN AND METHODS: We used flow activated cell sorting analysis to compare the distribution of the T-cell receptor-Vβ repertoire and several surface molecules (CD7, CD26, CD49d and CD60) within the circulating CD4(+) T-cell population in 62 patients with Sézary syndrome, 180 with mycosis fungoides, 6 with B-cell lymphomas, and 19 with chronic eczema. We calculated the 5-year overall survival of patients with Sézary syndrome after first hospital admission using Kaplan-Meier product-limit estimates and hazard ratios from the Cox proportional hazards model. RESULTS: We found that both higher number of CD60(+) and lower number of CD49d(+) cells within circulating CD4(+) T cells at disease presentation were significantly associated with a lower probability of survival. An exceedingly high risk of death was observed for patients with a combination of a high proportion of CD4(+)CD60(+) cells (≥ 0.5×10(9)/L) and low proportion of CD4(+)CD49d(+) cells (<0.5×10(9)/L) (hazard ratio = 12.303, 95% confidence interval 1.5-95.9; P<0.02). In addition, a skewed usage of T-cell receptor-Vβ subfamilies was observed in the circulating T-cell clone for 61.9% of all patients with Sézary syndrome, T-cell receptor-Vβ 2 and 5.1 subfamilies being the most frequently represented (42.8%), followed by T-cell receptor-Vβ 12 and 13.1. CONCLUSIONS: In this study we showed that up-regulation of CD60 and down-regulation of CD49d on circulating CD4(+) T cells are two useful markers for predicting a very poor outcome in patients with Sézary syndrome.
Authors: T M Zollner; T A Wichelhaus; A Hartung; C Von Mallinckrodt; T O Wagner; V Brade; R Kaufmann Journal: Clin Exp Allergy Date: 2000-07 Impact factor: 5.018
Authors: M Mempel; G Lina; M Hojka; C Schnopp; H-P Seidl; T Schäfer; J Ring; F Vandenesch; D Abeck Journal: Eur J Clin Microbiol Infect Dis Date: 2003-05-13 Impact factor: 3.267
Authors: M G Bernengo; P Quaglino; M Novelli; N Cappello; G C Doveil; F Lisa; A De Matteis; M T Fierro; A Appino Journal: Ann Oncol Date: 1998-08 Impact factor: 32.976
Authors: Terkild Brink Buus; Andreas Willerslev-Olsen; Simon Fredholm; Edda Blümel; Claudia Nastasi; Maria Gluud; Tengpeng Hu; Lise M Lindahl; Lars Iversen; Hanne Fogh; Robert Gniadecki; Ivan V Litvinov; Jenny L Persson; Charlotte Menné Bonefeld; Carsten Geisler; Jan Pravsgaard Christensen; Thorbjørn Krejsgaard; Thomas Litman; Anders Woetmann; Niels Ødum Journal: Blood Adv Date: 2018-08-28
Authors: Bernice M Benoit; Neha Jariwala; Geraldine O'Connor; Landon K Oetjen; Timothy M Whelan; Adrienne Werth; Andrea B Troxel; Hélène Sicard; Lisa Zhu; Christopher Miller; Junko Takeshita; Daniel W McVicar; Brian S Kim; Alain H Rook; Maria Wysocka Journal: Arch Dermatol Res Date: 2016-10-20 Impact factor: 3.017
Authors: Maria Wysocka; Andrew V Kossenkov; Bernice M Benoit; Andrea B Troxel; Elisha Singer; Andras Schaffer; Brian Kim; Tzvete Dentchev; Satoshi Nagata; Tomoko Ise; Louise C Showe; Alain H Rook Journal: J Invest Dermatol Date: 2013-06-21 Impact factor: 8.551